• News
    • Featured Articles
    • Product News
    • E-News
  • Magazine
    • About us
    • Digital edition
    • Archived issues
    • Free subscriptions
    • Media kit
    • Submit Press Release
  • White Papers
  • Events
  • Suppliers
  • E-Alert
  • Contact us
  • FREE newsletter subscription
  • Search
  • Menu Menu
Clinical Laboratory int.
  • Allergies
  • Cardiac
  • Gastrointestinal
  • Hematology
  • Microbiology
  • Microscopy & Imaging
  • Molecular Diagnostics
  • Pathology & Histology
  • Protein Analysis
  • Rapid Tests
  • Therapeutic Drug Monitoring
  • Tumour Markers
  • Urine Analysis

Archive for category: E-News

E-News

AzentaGenomics

Azenta selects Oxford for new genomic services facility

, 17 January 2024/in E-News /by panglobal

Azenta Life Sciences has selected Oxford, UK, a key European life sciences hub, as the location for its next GENEWIZ Multiomics and Synthesis Solutions site. The site will feature a new state-of-the-art genomics lab scheduled to begin full operations in March this year.

Read more
https://clinlabint.com/wp-content/uploads/sites/2/2024/01/AzentaGenomics.jpg 680 768 panglobal https://clinlabint.com/wp-content/uploads/sites/2/2020/06/clinlab-logo.png panglobal2024-01-17 10:38:302024-01-17 10:38:30Azenta selects Oxford for new genomic services facility
shutterstock 2334008633

MIMETAS and Yamaha Motor sign joint marketing agreement to advance automated human disease model applications for drug development

, 17 January 2024/in E-News /by panglobal

MIMETAS, a leader in human 3D disease modelling, and Yamaha Motor Co., a developer of the Cell Handler, have singed a strategic joint marketing agreement aimed at advancing therapeutic development using human-relevant models throughout the early drug development pipeline. The collaboration combines MIMETAS’ comprehensive disease modelling and assay development expertise with Yamaha Motor’s state-of-the-art Cell […]

Read more
https://clinlabint.com/wp-content/uploads/sites/2/2024/01/shutterstock_2334008633.jpg 1084 1920 panglobal https://clinlabint.com/wp-content/uploads/sites/2/2020/06/clinlab-logo.png panglobal2024-01-17 10:21:392024-01-17 10:25:28MIMETAS and Yamaha Motor sign joint marketing agreement to advance automated human disease model applications for drug development
CN Bio Tomasz Kostrzewski

CN Bio PhysioMimix Organ-on-a-Chip data supports Inipharm study of INI-822 for metabolic liver disease treatment

, 17 January 2024/in E-News /by panglobal

CN Bio, a leading Organ-on-a-Chip (OOC) company, says its PhysioMimix assay for Non-alcoholic steatohepatitis (NASH) was important for confirmation of efficacy for INI-822 from Inipharm.

Read more
https://clinlabint.com/wp-content/uploads/sites/2/2024/01/CN-Bio-Tomasz_Kostrzewski.jpg 828 566 panglobal https://clinlabint.com/wp-content/uploads/sites/2/2020/06/clinlab-logo.png panglobal2024-01-17 10:18:592024-01-17 10:18:59CN Bio PhysioMimix Organ-on-a-Chip data supports Inipharm study of INI-822 for metabolic liver disease treatment
shutterstock 1045064908

Verici DX signs global licensing and commercialisation agreement with Thermo Fisher Scientific

, 17 January 2024/in E-News /by panglobal

Verici Dx, a developer of advanced clinical diagnostics for organ transplant, has signed an exclusive global licensing agreement with Thermo Fisher Scientific to further develop an assay for pre-transplant prognostic testing for risk of early kidney rejection.

Read more
https://clinlabint.com/wp-content/uploads/sites/2/2024/01/shutterstock_1045064908.jpg 1275 1920 panglobal https://clinlabint.com/wp-content/uploads/sites/2/2020/06/clinlab-logo.png panglobal2024-01-17 10:15:162024-01-17 10:15:16Verici DX signs global licensing and commercialisation agreement with Thermo Fisher Scientific
alzh

PharmaKure and Universiti Teknologi MARA (UiTM) announce partnership to advance research in Alzheimer’s Disease diagnosis

, 13 December 2023/in E-News /by panglobal

Research partnership aims to build strong pharma and academic collaborations in sharing data and clinical samples to develop biomarker-based diagnostics for Alzheimer’s Disease 

Read more
https://clinlabint.com/wp-content/uploads/sites/2/2023/12/alzh.jpg 428 920 panglobal https://clinlabint.com/wp-content/uploads/sites/2/2020/06/clinlab-logo.png panglobal2023-12-13 13:08:102023-12-13 13:08:10PharmaKure and Universiti Teknologi MARA (UiTM) announce partnership to advance research in Alzheimer’s Disease diagnosis
Lab 1

Nanologica Receives Order of Purification Media Worth Approx. MSEK 3.6

, 30 November 2023/in E-News /by panglobal

Nanologica expands its product portfolio of purification medias for preparative chromatography and has received a trial order worth approximately MSEK 3.6 from a customer in Asia.

Read more
https://clinlabint.com/wp-content/uploads/sites/2/2023/11/Lab-1.jpg 1920 1280 panglobal https://clinlabint.com/wp-content/uploads/sites/2/2020/06/clinlab-logo.png panglobal2023-11-30 08:56:242023-11-30 08:56:24Nanologica Receives Order of Purification Media Worth Approx. MSEK 3.6
IBB UAB researchers

Researchers develop most comprehensive database for the study of protein aggregation

, 8 November 2023/in E-News /by panglobal

Researchers at the IBB-UAB have developed the most comprehensive database available to date to help understand the basis of protein aggregation, a phenomenon associated with ageing and several pathologies. The new resource, A3D-MOBD [1], brings together the proteomes of 12 of the most studied model organisms which cover distant biological clades and contains over half […]

Read more
https://clinlabint.com/wp-content/uploads/sites/2/2023/11/IBB-UAB-researchers.jpg 1096 1486 panglobal https://clinlabint.com/wp-content/uploads/sites/2/2020/06/clinlab-logo.png panglobal2023-11-08 16:37:102023-11-08 16:38:21Researchers develop most comprehensive database for the study of protein aggregation
alpha synuclein

Dual role of alpha-synuclein in calcium regulation may have major implications for Parkinson’s disease process

, 8 November 2023/in E-News /by panglobal

The protein alpha-synuclein (aSN) has long been known as a main cause in Parkinson’s disease and Lewy Body Dementia, for example, when it forms lumpy protein aggregates that destroy cell function – but aSN in its natural form, without clumping, has not had a concrete, known function.

Read more
https://clinlabint.com/wp-content/uploads/sites/2/2023/11/alpha-synuclein.jpg 509 700 panglobal https://clinlabint.com/wp-content/uploads/sites/2/2020/06/clinlab-logo.png panglobal2023-11-08 16:18:252023-11-08 16:19:31Dual role of alpha-synuclein in calcium regulation may have major implications for Parkinson’s disease process
Fapon and Halodoc Forge Strategic Partnership

Fapon and Halodoc forge strategic partnership to drive the development of Indonesia’s in-vitro diagnostics Industry

, 8 November 2023/in E-News /by panglobal

Guangdong, China-based Fapon, a global life-science and biotech company, signed a strategic cooperation agreement with Halodoc, the largest telehealth platform in Indonesia. This partnership brings together Fapon’s expertise in in-vitro diagnostics (IVD) technologies and integrated solutions with Halodoc’s strong sales channels and local service provisions. The partnership aims to enhance the healthcare standards in Indonesia, […]

Read more
https://clinlabint.com/wp-content/uploads/sites/2/2023/11/Fapon-and-Halodoc-Forge-Strategic-Partnership.jpg 579 633 panglobal https://clinlabint.com/wp-content/uploads/sites/2/2020/06/clinlab-logo.png panglobal2023-11-08 14:39:192023-11-08 14:39:19Fapon and Halodoc forge strategic partnership to drive the development of Indonesia’s in-vitro diagnostics Industry
shutterstock 2189901805

Semarion announces early adopter programme for SemaCyte Microcarrier Platform

, 8 November 2023/in E-News /by panglobal

Semarion, a University of Cambridge spin-out company from the Cavendish Laboratory combining materials engineering and cell biology to tackle unmet drug screening needs, announced the opening of its Early Adopter Programme for its SemaCyte Microcarrier Platform. The platform overcomes current limitations associated with adherent cell culture and assaying workflows by enabling small colonies of cells […]

Read more
https://clinlabint.com/wp-content/uploads/sites/2/2023/11/shutterstock_2189901805.jpg 624 1920 panglobal https://clinlabint.com/wp-content/uploads/sites/2/2020/06/clinlab-logo.png panglobal2023-11-08 14:35:582023-11-08 14:35:58Semarion announces early adopter programme for SemaCyte Microcarrier Platform
Page 33 of 233«‹3132333435›»
Bio-Rad - Preparing for a Stress-free QC Audit

Latest issue of Clinical laboratory

May 2026

CLi Cover May 2026
17 June 2026

T-CURX acquires Pantherna Therapeutics to fast-track non-viral in vivo CAR-T therapies into the clinic

17 June 2026

Cirena secures Agilent licensing deal to unlock high-purity long RNA production

17 June 2026

SLAS Europe 2026: Trince takes top ignite award as Vienna conference draws 1,500-plus registrants

Digital edition
All articles Archived issues

Free subscription

View more product news

Get our e-alert

The leading international magazine for Clinical laboratory Equipment for everyone in the Vitro diagnostics

Sign up today
  • News
    • Featured Articles
    • Product News
    • E-News
  • Magazine
    • About us
    • Archived issues
    • Free subscriptions
    • Media kit
    • Submit Press Release
clinlab logo blackbg 1

Prins Hendrikstraat 1
5611HH Eindhoven
The Netherlands
info@clinlabint.com

PanGlobal Media is not responsible for any error or omission that might occur in the electronic display of product or company data.

Scroll to top

This site uses cookies. By continuing to browse the site, you are agreeing to our use of cookies.

Accept settingsHide notification onlyCookie settings

Cookie and Privacy Settings



How we use cookies

We may ask you to place cookies on your device. We use cookies to let us know when you visit our websites, how you interact with us, to enrich your user experience and to customise your relationship with our website.

Click on the different sections for more information. You can also change some of your preferences. Please note that blocking some types of cookies may affect your experience on our websites and the services we can provide.

Essential Website Cookies

These cookies are strictly necessary to provide you with services available through our website and to use some of its features.

Because these cookies are strictly necessary to provide the website, refusing them will affect the functioning of our site. You can always block or delete cookies by changing your browser settings and block all cookies on this website forcibly. But this will always ask you to accept/refuse cookies when you visit our site again.

We fully respect if you want to refuse cookies, but to avoid asking you each time again to kindly allow us to store a cookie for that purpose. You are always free to unsubscribe or other cookies to get a better experience. If you refuse cookies, we will delete all cookies set in our domain.

We provide you with a list of cookies stored on your computer in our domain, so that you can check what we have stored. For security reasons, we cannot display or modify cookies from other domains. You can check these in your browser's security settings.

.

Google Analytics Cookies

These cookies collect information that is used in aggregate form to help us understand how our website is used or how effective our marketing campaigns are, or to help us customise our website and application for you to improve your experience.

If you do not want us to track your visit to our site, you can disable this in your browser here:

.

Other external services

We also use various external services such as Google Webfonts, Google Maps and external video providers. Since these providers may collect personal data such as your IP address, you can block them here. Please note that this may significantly reduce the functionality and appearance of our site. Changes will only be effective once you reload the page

Google Webfont Settings:

Google Maps Settings:

Google reCaptcha settings:

Vimeo and Youtube videos embedding:

.

Privacy Beleid

U kunt meer lezen over onze cookies en privacy-instellingen op onze Privacybeleid-pagina.

Privacy policy
Accept settingsHide notification only

Subscribe now!

Become a reader.

Free subscription